Guardant Health (FRA:5GH) Beginning Cash Position : €1,043.0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Guardant Health Beginning Cash Position?

Guardant Health's Beginning Cash Position for the quarter that ended in Mar. 2024 was €1,043.0 Mil.

Guardant Health's quarterly Beginning Cash Position increased from Sep. 2023 (€254.1 Mil) to Dec. 2023 (€419.4 Mil) and increased from Dec. 2023 (€419.4 Mil) to Mar. 2024 (€1,043.0 Mil).

Guardant Health's annual Beginning Cash Position declined from Dec. 2021 (€737.2 Mil) to Dec. 2022 (€464.7 Mil) and declined from Dec. 2022 (€464.7 Mil) to Dec. 2023 (€130.2 Mil).

Guardant Health Beginning Cash Position Historical Data

The historical data trend for Guardant Health's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Guardant Health Beginning Cash Position Chart

Guardant Health Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

126.49

117.73

737.18

464.72

130.17

Guardant Health Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Beginning Cash Position	Get a 7-Day Free Trial															132.58	206.49	254.09	419.40	1,042.99

Guardant Health Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Guardant Health Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Guardant Health's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Guardant Health (FRA:5GH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Guardant Health Inc (FRA:5GH) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

GH:USA

Address

3100 Hanover Street, Palo Alto, CA, USA, 94304

Website

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

Guardant Health (FRA:5GH) Headlines

No Headlines